Skip to main content

Rhythm Pharmaceuticals (RYTM) Receives a Buy from TD Cowen

Tipranks - Tipranks - Sat Jan 10, 12:16PM CST

TD Cowen analyst Phil Nadeau maintained a Buy rating on Rhythm Pharmaceuticals today and set a price target of $130.00.

Claim 70% Off TipRanks Premium

Nadeau covers the Healthcare sector, focusing on stocks such as Kura Oncology, Rhythm Pharmaceuticals, and Apellis Pharmaceuticals. According to TipRanks, Nadeau has an average return of 7.1% and a 47.72% success rate on recommended stocks.

In a report released today, Needham also maintained a Buy rating on the stock with a $148.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Rhythm Pharmaceuticals’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $51.3 million and a GAAP net loss of $52.9 million. In comparison, last year the company earned a revenue of $33.25 million and had a GAAP net loss of $43.64 million

Read More on RYTM:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).